On Wednesday, Electronic Arts Inc. (NASDAQ:EA)’s shares inclined 2.65% to $67.75.
Be reckless. Be Respected. Electronic Arts (EA) invites you to leave your rivals in the dust as you leave your mark on the world of street racing in Need for Speed™ No Limits, built exclusively for mobile and accessible recently as a free download* in the App Store and Google Play.
Earn respect on the streets of Blackridge by pushing your skills to the limits - speed over jumps, weave through traffic, and blast through high-speed Nitro Zones. Make your own rules, personalize your ride and make a name for yourself in hundreds of adrenaline-fueled arcade race events.
Electronic Arts Inc. develops, markets, publishes, and distributes game software content and online services for video game consoles, Internet-connected consoles, personal computers, mobile phones, and tablets worldwide. The company operates through EA Studios, EA Mobile, and Maxis divisions.
Akamai Technologies, Inc. (NASDAQ:AKAM)’s shares gained 2.31% to $69.06.
WhereverTV Broadcasting Corp. (TVTV), declared that it is ongoing to improve and expand its content delivery assets, secure improved digital technologies, and expand its administration team to gear up for growth in the delivery of real-time and live-streaming OTT content to consumers who prefer to watch content on a mobile or internet connected device. As part of this ongoing strategy, WhereverTV also declared that it has contracted with Akamai Technologies, Inc. (AKAM), the global leader in Content Delivery Network (CDN) services, to enhance its user experience and content delivery platform.
Akamai’s Media Delivery solutions are designed to assist further enhance WhereverTV’s ability to deliver content to a variety of devices counting Connected TVs, streaming media players, smartphones and TabletPCs in addition to the ability to deliver that content in connection with its patented Interactive Program Guide technology. The relationship strengthens WhereverTV’s ability to broadcast to any device without regard to data speed constraints, and with very little latency issues often practiced with IPTV & OTT streaming or broadcasting.
Akamai Technologies, Inc. provides cloud services for delivering, optimizing, and securing online content and business applications in the United States and internationally.
At the end of Wednesday’s trade, Perrigo Company plc (NYSE:PRGO)‘s shares surged 1.38% to $157.03.
Perrigo Company plc (PRGO) declared it has received an AB therapeutic equivalent rating and final U.S. Food and Drug Administration (“FDA”) approval for the generic version of Valeant Pharmaceutical International, Inc.’s BenzaClin® Topical Gel. The FDA concluded that Perrigo’s product is therapeutically equivalent to BenzaClin® Gel 1%/5% and can be substituted with the full expectation that it will produce the same clinical effect and safety profile as BenzaClin® Gel 1%/5% when used under the conditions specified in the label. Shipments to customers will start right away.
BenzaClin® Topical Gel (clindamycin phosphate 1% and benzoyl peroxide 5%) is indicated for the topical treatment of acne vulgaris. Combined generic and branded sales for the twelve months ending July 2015 were $231 million.
Perrigo Company plc, through its auxiliaries, develops, manufactures, and markets over-the-counter (OTC) consumer goods and pharmaceutical products worldwide. The company operates through Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx Pharmaceuticals), Specialty Sciences, and Other segments.
Peregrine Pharmaceuticals (NASDAQ:PPHM), ended its Wednesday’s trading session with 0.99% gain, and closed at $1.02.
Peregrine Pharmaceuticals, Inc. (PPHM) (PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer, declared financial results for the first quarter of fiscal year (FY) 2016 ended July 31, 2015, and offered an update on its advancing clinical pipeline and other corporate developments.
Clinical Development Highlights
- Peregrine and AstraZeneca reached a cancer immunotherapy clinical trial partnership to evaluate bavituximab in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736). The planned Phase I/Ib trial will evaluate the safety and efficacy of bavituximab in combination with durvalumab in multiple solid tumors. Peregrine is working closely with AstraZeneca to finalize the trial design.
- Phase III SUNRISE clinical trial in non-small cell lung cancer (NSCLC) continues to enroll patients and remains on track to complete patient enrollment by end of calendar year 2015.
- Peregrine declared plans to expand the bavituximab clinical development program to comprise a Phase II trial to evaluate the combination of bavituximab and Opdivo® (nivolumab), an anti-PD-1 antibody, in formerly treated, metastatic NSCLC. This trial is predictable to be initiated by the end of calendar year 2015.
- Peregrine declared plans to expand the bavituximab clinical development program to comprise a Phase II/III trial to evaluate bavituximab with chemotherapy combinations in HER2-negative metastatic breast cancer. This trial is predictable to be initiated by the end of calendar year 2015.
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops monoclonal antibodies for the treatment and diagnosis of cancer in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
